Angiodynamic Inc (ANGO) concluded trading on Thursday at a closing price of $9.52, with 0.47 million shares of worth about $4.45 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 50.39% during that period and on April 17, 2025 the price saw a gain of about 0.63%. Currently the company’s common shares owned by public are about 40.97M shares, out of which, 38.73M shares are available for trading.
Stock saw a price change of 3.03% in past 5 days and over the past one month there was a price change of 1.28%. Year-to-date (YTD), ANGO shares are showing a performance of 3.93% which increased to 46.24% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.47 but also hit the highest price of $13.50 during that period. The average intraday trading volume for Angiodynamic Inc shares is 612.53K. The stock is currently trading -1.33% below its 20-day simple moving average (SMA20), while that difference is down -2.56% for SMA50 and it goes to 13.22% higher than SMA200.
Angiodynamic Inc (NASDAQ: ANGO) currently have 40.97M outstanding shares and institutions hold larger chunk of about 79.32% of that.
The stock has a current market capitalization of $386.58M and its 3Y-monthly beta is at 0.56. It has posted earnings per share of -$1.02 in the same period. It has Quick Ratio of 1.40 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ANGO, volatility over the week remained 4.33% while standing at 6.00% over the month.
Stock’s fiscal year EPS is expected to rise by 34.05% while it is estimated to increase by 10.11% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on April 05, 2024 offering an Outperform rating for the stock and assigned a target price of $12 to it. Coverage by H.C. Wainwright stated Angiodynamic Inc (ANGO) stock as a Buy in their note to investors on September 25, 2023, suggesting a price target of $19 for the stock. On April 17, 2023, Raymond James Downgrade their recommendations, while on October 15, 2021, Canaccord Genuity Upgrade their ratings for the stock with a price target of $37. Stock get a Perform rating from Oppenheimer on August 20, 2021.
